Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Irritable Bowel Syndrome (IBS) Treatment Market Value Growth And Long-Term Outlook
The irritable bowel syndrome (ibs) treatment market size has experienced robust growth in recent years. It is anticipated to increase from $7.41 billion in 2025 to $7.97 billion in 2026, with a compound annual growth rate (CAGR) of 7.6%. The historical expansion of this market can be attributed to the rising prevalence of gastrointestinal disorders, increased diagnosis rates of ibs, growing awareness of digestive health, the availability of prescription ibs drugs, and the expansion of hospital and retail pharmacy networks.
The irritable bowel syndrome (IBS) treatment market size is anticipated to demonstrate robust expansion in the upcoming years. It is projected to ascend to $10.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This projected increase is driven by factors such as progress in precision medicine, broader acceptance of digital health platforms, the proliferation of online pharmacy channels, a growing emphasis on microbiome research, and rising healthcare spending dedicated to chronic conditions. Significant developments expected during the forecast period involve precision medicine and microbiome-based therapies, the integration of digital therapeutics with mobile health, AI-powered IBS diagnosis and treatment optimization, remote patient monitoring coupled with smart gut health devices, and a shift towards sustainable, patient-centric drug development.
Get A Free Sample Report With In-Depth Market Insights:
Irritable Bowel Syndrome (IBS) Treatment Market Development Factors: What’s Supporting Demand?
The increasing occurrence of Irritable Bowel Syndrome (IBS) is anticipated to drive expansion within the IBS treatment market. IBS is a long-term digestive condition primarily affecting the large intestine, characterized by symptoms like constipation, diarrhea, abdominal discomfort, and bloating, which notably diminish an individual’s quality of life. This rise in IBS cases stems from various lifestyle elements such as inadequate diet, heightened stress levels, and environmental factors, all contributing to a greater number of people developing the condition. To meet patient demands, the IBS treatment market offers both drug-based solutions, like antispasmodics and medications specifically targeting the gut, alongside non-drug approaches, including cognitive behavioral therapy, hypnotherapy, and controlled diets. As an example, in December 2023, the IBD Registry, a UK-based non-profit organization, noted that it reached over 5,300 individuals with Inflammatory Bowel Disease (IBD) by 2023, which signifies an increase of more than 3,000 members compared to 2022. Consequently, the increasing prevalence of IBS is a significant factor propelling the expansion of the IBS treatment market.
Irritable Bowel Syndrome (IBS) Treatment Market Segment Trends And Revenue Contributors
The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –
1) By Drug Type: Eluxadoline, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment
2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment
3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Irritable Bowel Syndrome (IBS) Treatment Market Transformation Trends: What Innovations Are Driving Change?
Leading firms in the irritable bowel syndrome (IBS) treatment market are increasingly integrating digital therapeutic solutions, particularly mobile applications based on gut-directed hypnotherapy, to boost patient involvement, expand treatment availability, and enhance symptom handling. These gut-directed hypnotherapy mobile applications serve as prescribed digital platforms, offering structured hypnotherapy sessions via smartphones to adjust gut–brain interaction, thus supporting features like guided behavioral therapy, live symptom tracking, and automated patient progress oversight. An example of this trend is observed in May 2023, when Launchit DTx, a digital health commercialization company based in Canada, introduced Regulora. This digital therapeutic, utilizing gut-directed hypnotherapy, aims to assist adults in managing abdominal pain linked with irritable bowel syndrome (IBS), incorporating evidence-based hypnotherapy modules, prescribing workflows for clinicians, and a mobile application for tracking patient responses over time. By providing a non-pharmacologic, digitally delivered therapeutic option, Regulora improves treatment accessibility, self-management capabilities, and general symptom alleviation for individuals suffering from IBS.
Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.
View The Full Irritable Bowel Syndrome (IBS) Treatment Market Report:
Irritable Bowel Syndrome (IBS) Treatment Market Regional Analysis And Top Geography
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









